CONBA(SH:600572)2018-04-25 16:00Financial Performance - The company achieved operating revenue of RMB 1.782 billion in Q1 2018, a year-on-year increase of 62.51%[5] - The net profit attributable to shareholders reached RMB 267.88 million, up 41.75% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 229.67 million, reflecting a growth of 20.15% year-on-year[5] - The company's revenue for the first quarter reached ¥1,782,258,348.99, representing a 62.51% increase compared to ¥1,096,734,420.37 in the same period last year[16] - Total operating revenue for Q1 2018 reached CNY 1,782,258,348.99, a significant increase of 62.5% compared to CNY 1,096,734,420.37 in the same period last year[36] - Net profit for Q1 2018 was CNY 267,526,578.81, representing a 42.1% increase from CNY 188,234,724.55 in Q1 2017[37] - The total comprehensive income attributable to the parent company was CNY 267.54 million, compared to CNY 189.50 million in the same period last year, reflecting a growth of 41.2%[38] Sales and Revenue Growth - Sales revenue from major brand products under the "Big Brand Big Variety Project" totaled RMB 1.28 billion, an increase of 81.85%[6] - The "Kang En Bei" brand's "Chronic Enteritis Ning" series products generated sales of RMB 203.72 million, growing by 135.78%[6] - The sales volume of "Xutong" brand Dan Shen Chuan Xiong injection increased by 6.68% year-on-year, with sales revenue reaching RMB 369.83 million, up 161.12%[6] Cash Flow and Financial Position - The net cash flow from operating activities was RMB 133.55 million, a decrease of 30.50% compared to the same period last year[5] - Operating cash flow decreased by 30.50% year-on-year, mainly due to increased payments for goods and expenses[19] - Cash flow from operating activities for Q1 2018 was CNY 133.55 million, down 30.5% from CNY 192.16 million in Q1 2017[43] - The company reported a net cash outflow from investing activities of CNY 107.02 million, compared to an outflow of CNY 155.47 million in the previous year[44] - The company's cash and cash equivalents decreased to CNY 1,027,373,617.04 from CNY 1,295,982,400.08 at the beginning of the year, a decline of 20.7%[31] - The ending cash and cash equivalents balance was $1,026,774,441.09, down from $1,295,383,224.13, reflecting a decrease of approximately 20.7%[47] Investment and Assets - The company completed a private placement of 156.5902 million shares at RMB 6.98 per share, raising a total of RMB 1.0929996 billion for its international advanced pharmaceutical base project[20] - The company acquired 41% equity in Jiangxi Tianshi Kang Chinese Medicine Co., Ltd. for RMB 300.35 million, resulting in a 100% ownership stake post-acquisition[22] - The total assets as of March 31, 2018, amounted to RMB 9.575659 billion, an increase from RMB 9.420221 billion at the beginning of the year[28] - The balance of long-term prepaid expenses grew by 130.42% from ¥17,841,421.61 to ¥41,110,564.70, due to the completion of office renovations[15] - The balance of other non-current assets increased by 81.49% from ¥22,812,128.65 to ¥41,400,780.34, mainly due to advances for equipment purchases[15] Expenses and Liabilities - Total operating costs for Q1 2018 were CNY 1,509,610,077.99, up 74.5% from CNY 864,945,176.23 in Q1 2017[37] - Sales expenses surged by 140.21% from ¥374,745,084.32 to ¥900,182,953.88, reflecting increased investment in marketing and brand development[17] - Total liabilities decreased slightly to CNY 1,990,301,064.04 from CNY 1,996,716,686.63 at the start of the year[33] Other Income and Gains - The company reported a 312.21% increase in fair value changes, with gains of ¥18,526,853.17 compared to losses of ¥8,730,436.74 in the previous year[16] - Other income rose by 46.59% year-on-year, attributed to government subsidies received by the subsidiary Jinhua Kang En Bei amounting to RMB 5.84 million[18] - Asset disposal income increased by 532.73% compared to the previous year, driven by higher asset disposal gains from the subsidiary Jinhua Kang En Bei[18] - The company experienced a 96.50% decrease in asset impairment losses, from ¥3,922,174.49 to ¥137,293.80, due to the recovery of long-aged receivables[17] Strategic Focus - The company plans to enhance investment in marketing team development and market network expansion[7] - The company is focusing on innovation and leveraging brand advantages to seek new breakthroughs and development opportunities[6]